Jennerex Biotherapeutics Inc, based in San Francisco, CA, is a global leader in oncolytic immunotherapeutics, specializing in targeting, attacking, and eradicating cancers. Their most advanced product candidate, Pexa Vec, is engineered to selectively infect and replicate in cancer cells by leveraging genetic changes common in cancer cells.
In addition to Pexa Vec, Jennerex Biotherapeutics is actively developing their next-generation pipeline, JX 970, which has shown promising tumor debulking effects and a selective preference for tumor tissues in preclinical studies. The company is dedicated to advancing innovative treatments for cancer through strategic partnerships and ongoing research efforts.
Generated from the website